Years of in-house research at Marinus resulted in the invention of a patented nanoparticulate composition for solid and liquid oral dose forms of ganaxolone that are highly stable and provide good exposure. This discovery resulted in the issuance of U.S. and foreign patents covering use of these complex ganaxolone nanoparticles in solid and liquid dose forms.
The nanoparticulate composition patents for oral liquid and solid dose forms of ganaxolone are expected to provide intellectual property protection through at least 2026. This application identified a novel process using an organometallic methylating agent, which is significantly more cost effective in the manufacture of ganaxolone than previous processes. This synthesis patent is expected to provide intellectual property protection through at least 2030.